What is Leerink Partnrs’ Estimate for MLTX FY2029 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTXFree Report) – Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of $8.17 per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

A number of other research firms have also commented on MLTX. Wedbush reaffirmed an “outperform” rating and issued a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th. Finally, The Goldman Sachs Group raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $62.00 to $82.00 in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Buy” and an average price target of $84.29.

Read Our Latest Analysis on MLTX

MoonLake Immunotherapeutics Trading Up 1.0 %

MoonLake Immunotherapeutics stock opened at $47.11 on Friday. The firm has a 50 day simple moving average of $50.02 and a 200 day simple moving average of $49.04. MoonLake Immunotherapeutics has a 1-year low of $37.55 and a 1-year high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTXGet Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the prior year, the firm earned ($0.18) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE bought a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $44,000. Barclays PLC raised its position in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after buying an additional 5,229 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of MoonLake Immunotherapeutics by 26.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock worth $655,000 after acquiring an additional 2,700 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in MoonLake Immunotherapeutics in the third quarter worth $706,000. Finally, Erste Asset Management GmbH purchased a new position in MoonLake Immunotherapeutics in the third quarter worth $741,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Featured Stories

Earnings History and Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.